PMC:4307189 / 51087-51620 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4307189","sourcedb":"PMC","sourceid":"4307189","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4307189","text":"Our results primarily focus on compensatory signaling pathways i.e. Notch signaling, Wnt signaling, GPCR signaling, and IR/IGF1R signaling, which cross-talk with EGFR/ErbB signaling to reduce the inhibiting effect of lapatinib. We present additional literature evidence that the identified cross-talks of the above compensatory signaling pathways with EGFR/ErbB signaling may contribute to drug-resistance by maintaining key cell survival and/or proliferation signals in common down-stream pathways, including PI3K/Akt signaling [1].","tracks":[{"project":"2_test","denotations":[{"id":"25599599-23542173-14868175","span":{"begin":530,"end":531},"obj":"23542173"}],"attributes":[{"subj":"25599599-23542173-14868175","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ec93a1","default":true}]}]}}